PA
GSK icon

PFG Advisors’s GSK GSK Stock Holding History

PFG Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,441
Closed -$372K – 637
2023
Q2 		$372K Sell
10,441
-2,340
-18% -$83.9K 0.03% 459
2023
Q1 		$455K Sell
12,781
-3,374
-21% -$118K 0.04% 405
2022
Q4 		$568K Sell
16,155
-3,589
-18% -$120K 0.06% 331
2022
Q3 		$581K Sell
19,744
-1,661
-8% -$63K 0.07% 304
2022
Q2 		$1.17M Buy
21,405
+591
+3% +$32.6K 0.13% 156
2022
Q1 		$1.13M Sell
20,814
-1,304
-6% -$70.8K 0.11% 179
2021
Q4 		$1.22M Sell
22,118
-3,204
-13% -$167K 0.12% 213
2021
Q3 		$1.21M Sell
25,322
-1,988
-7% -$99.9K 0.13% 211
2021
Q2 		$1.36M Sell
27,310
-592
-2% -$28.4K 0.16% 186
2021
Q1 		$1.25M Buy
+27,902
New +$1.27M 0.16% 180

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PFG Advisors's GSK Position: Q3 2023 in Review

PFG Advisors sold out of GSK (GSK) in Q3 2023, closing a stake of 10,441 shares — an estimated $372K sold.

PFG Advisors first reported a position in GSK in Q1 2021 and held it in 10 quarters. The position peaked at $1.36M in Q2 2021. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

  • PFG Advisors reported no remaining GSK position as of Q3 2023 after selling out during the quarter.
  • PFG Advisors sold 10,441 GSK shares in Q3 2023, an estimated $372K.
  • PFG Advisors first reported a position in GSK in Q1 2021 and held it in 10 quarters.
  • PFG Advisors's GSK position peaked at $1.36M in Q2 2021.
  • 846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on PFG Advisors's 13F filing for Q3 2023, filed 13 Oct 2023.